DNA Manufacturing Market Growth & Trends:
The global DNA manufacturing market size is projected to reach USD 14.96 billion by 2030, growing at a CAGR of 18.10% from 2025 to 2030, according to a new report by Grand View Research, Inc. The DNA manufacturing market is rapidly evolving, driven by rising demand for synthetic biology applications, personalized therapeutics, and advanced vaccine development. Increasing collaboration between biotech firms, academic institutions, and contract development and manufacturing organizations (CDMOs) is accelerating innovation and expanding market access. Technological advancements in gene synthesis, enzymatic DNA production, and automation enhance DNA manufacturing processes' scalability, speed, and precision.
This market is gaining momentum due to its critical role in various applications, including gene therapy, mRNA vaccines, diagnostic assay development, and cell engineering. As the need for high-quality plasmid DNA and GMP-grade materials grows, startups and legacy providers are expanding their capabilities to meet global demand.
Innovations in enzymatic synthesis, cell-free systems, and continuous manufacturing are reshaping traditional workflows and enabling faster turnaround times. These advancements support the broader adoption of DNA-based tools in oncology, infectious diseases, and regenerative medicine.
As the field matures, the DNA manufacturing market is positioned to be central in advancing the next generation of biotherapeutics, diagnostics, and precision health solutions.
DNA Manufacturing Market Report Highlights:
- Based on type, synthetic DNA dominated the DNA manufacturing market in 2024. This dominance is attributed to its flexibility, scalability, and expanding role in synthetic biology, genome editing, diagnostics, and next-generation therapeutics. Advances in enzymatic synthesis and automation have significantly reduced production time and costs, enabling the rapid, high-fidelity generation of custom DNA sequences. As demand grows for precision-engineered DNA across pharmaceutical, agricultural, and industrial biotech sectors, synthetic DNA continues to outpace traditional methods in innovation and adoption.
- Based on grade, R&D-grade DNA dominated the DNA manufacturing market in 2024. This dominance is primarily due to the widespread use of research-grade DNA in academic institutions, biotech startups, and early-stage drug development. Innovation in gene editing, synthetic biology, and vaccine research accelerates, and demand for cost-effective, high-quality DNA for experimental and preclinical studies continues to rise. The flexibility and faster turnaround of R&D-grade DNA make it an essential resource in iterative testing, proof-of-concept studies, and technology development.
- Based on application, cell and gene therapy dominated the DNA manufacturing market in 2024, accounting for 43.90% market share. This leadership is driven by the rapid advancement of gene-based therapeutic platforms targeting cancer, rare genetic disorders, and regenerative medicine. High demand for high-purity plasmid and synthetic DNA for use as vectors, templates, or raw material in cell and gene therapy pipelines has significantly increased production requirements.
- Based on end use, pharmaceutical and biotechnology companies dominated the DNA manufacturing market in 2024, accounting for 48.68% market share. The surge in demand for DNA-based inputs across gene therapy, vaccine production, and biologics development drives this dominance. As these companies advance clinical pipelines and bring novel therapeutics to market, their reliance on high-quality, scalable DNA manufacturing continues to grow. The increasing adoption of DNA technologies in precision medicine, oncology, and rare disease treatment further reinforces this segment's leadership.
- In May 2025, VGXI, Inc., a contract development and manufacturing organization (CDMO) specializing in nucleic acid-based therapeutics, announced the successful completion of a U.S. Food and Drug Administration (FDA) inspection at its Conroe, Texas facility. This milestone enables VGXI's client to submit a Biologics License Application (BLA) for clinical trials involving plasmid DNA, a critical component in gene therapies and mRNA vaccines. VGXI's achievement underscores its leadership in plasmid DNA manufacturing, offering scalable and high-purity production capabilities. The company has been a trusted partner in advancing life-changing medical research and innovation worldwide